Understanding Dose Equivalents: Expert Clinical Comparison
Mounjaro vs Wegovy Dose Equivalent: Key Mechanism Differences
When evaluating Mounjaro vs Wegovy dose equivalent options, the fundamental difference lies in their mechanisms of action rather than direct dose conversions. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics a single natural hormone pathway. Mounjaro contains tirzepatide, which acts on both GIP and GLP-1 receptors as a dual agonist. This means there isn't a simple "equivalent dose" between the two medications, as they work through different pathways in the body.
Both prescription-only medicines require clinical assessment and follow distinct escalation schedules designed to minimise side effects whilst optimising efficacy. Wegovy's dose escalation spans 16 weeks to reach the 2.4mg maintenance dose, whilst Mounjaro follows its own protocol to reach maintenance levels. Your prescriber will determine the most appropriate treatment based on your individual clinical profile rather than attempting direct dose conversions.
Wegovy Dose Escalation Schedule and UK Pricing
Wegovy follows a carefully structured dose escalation that cannot be rushed or modified. The schedule begins with 0.25mg for weeks 1-4 (£79.99), progressing to 0.5mg for weeks 5-8 (£94.99), then 1mg for weeks 9-12 (£99.99). Patients then advance to 1.7mg for weeks 13-16 (£139.99) before reaching the maintenance dose of 2.4mg from week 17 onwards (£209.99). New customers can apply discount code FIRST40 at checkout, whilst returning customers use DOSE25.
For those seeking convenience, our bundled options provide multiple doses in a single order. The Intro Trio bundle (0.25mg, 0.5mg & 1mg) costs £299.99 and covers the first 12 weeks of treatment. Our Ultimate Stability Trio provides three months of maintenance 2.4mg supply for £649.99, ensuring consistent treatment without the need for frequent reorders. These bundles offer the convenience of Reliable Supply and reduce the administrative burden of multiple orders.
Clinical Evidence: STEP Trials vs SURMOUNT Studies
In clinical trials, patients taking Wegovy alongside diet and exercise achieved an average weight loss of approximately 15% at 68 weeks in the STEP 1 trial (Wilding et al., NEJM, 2021). The STEP programme demonstrated consistent efficacy across different patient populations, with STEP 2 showing ~clinically studied weight loss in patients with type 2 diabetes. These results represent average outcomes from controlled clinical trials and individual results may vary.
Mounjaro's efficacy data comes from the SURMOUNT trial programme, which used different study designs, endpoints, and patient populations. Due to these methodological differences, direct comparison of weight loss percentages between the two medications would not provide meaningful clinical guidance. Both medications have demonstrated significant efficacy in their respective clinical programmes when used as part of a comprehensive weight management approach.
How Wegovy Works: GLP-1 Receptor Mechanism
Wegovy works by targeting GLP-1 receptors in the brain and digestive system, mimicking the action of a naturally occurring hormone called glucagon-like peptide-1. This mechanism helps reduce appetite by signalling feelings of fullness to the brain's appetite control centres. The medication slows gastric emptying, meaning food stays in the stomach longer, contributing to prolonged satiety after meals. Additionally, Wegovy may help reduce food cravings and the psychological drive to eat, supporting adherence to a reduced-calorie diet. These combined effects create a physiological environment that supports sustainable weight management when paired with lifestyle modifications.
Streamlined UK Ordering Process for Wegovy
Our ordering process begins with a comprehensive 3-minute online clinical assessment that evaluates your suitability for Wegovy treatment. Once submitted, our qualified prescribers review your assessment within 3 working days (or 24 hours with express review), ensuring all clinical criteria are met before approval. Upon prescription approval, your Wegovy is dispatched via next-day delivery using temperature-controlled packaging to maintain the medication's integrity. All orders are processed through our GPhC-registered pharmacy (#9012878), ensuring full regulatory compliance and clinical oversight. This streamlined approach means you can access Wegovy without lengthy waiting times or complex appointment booking systems.
Storage Advantages: Wegovy vs Mounjaro Practical Differences
One practical advantage when comparing Mounjaro vs Wegovy dose equivalent considerations is storage flexibility. Wegovy can be stored at room temperature (below 30°C) for up to 6 weeks once removed from refrigerated storage, compared to Mounjaro's 21-day room temperature limit. This makes Wegovy more suitable for travel or situations where refrigeration access may be limited. Both medications use pre-filled injection pens with dose counters, but Wegovy's FlexTouch pen design offers a slightly different user experience. The extended room temperature storage capability of Wegovy provides additional peace of mind for patients with active lifestyles or frequent travel commitments.
Why Both Medications Are Available Without Waitlists
Unlike the supply challenges experienced in 2023, both Wegovy and Mounjaro are now readily available through our established supply chains. Our direct relationships with Novo Nordisk ensure consistent Wegovy stock levels across all five dose strengths, eliminating the uncertainty that previously affected UK availability. We maintain strategic inventory levels to prevent stockouts, particularly for the popular starter doses and maintenance strengths.
This reliable availability means patients can begin treatment when clinically appropriate rather than waiting for supply to become available. Our procurement team monitors demand patterns and adjusts inventory accordingly, ensuring that both new patients starting dose escalation and existing patients requiring maintenance doses can access their prescribed medications without delays. This stock reliability removes a significant barrier that previously complicated treatment planning.
Expert Clinical Support for Treatment Selection
Rather than focusing solely on Mounjaro vs Wegovy dose equivalent comparisons, our clinical team evaluates multiple factors to determine the most appropriate treatment option. These considerations include your medical history, current medications, lifestyle factors, and individual treatment goals. Some patients may be better suited to Wegovy's single-receptor mechanism, whilst others might benefit from Mounjaro's dual-receptor approach. Our prescribers provide personalised recommendations based on current clinical guidelines and your specific circumstances.
This individualised approach ensures you receive the most appropriate prescription-only medicine for your situation. Both Wegovy and Mounjaro are available from EverydayMeds, and your prescriber can help determine which treatment aligns best with your clinical profile and weight management objectives. Regular monitoring and dose adjustments are included as part of our ongoing clinical support throughout your treatment journey.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
